CHMP Recommends Against Renewal of Marketing Authorization for Belantamab Mafodotin in R/R Myeloma

September 18, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against renewal of the conditional marketing authorization for belantamab maf

Updated on: October 24,2023 77

CHMP Recommends Against Renewal of Marketing Authorization for Belantamab Mafodotin in R/R Myeloma

September 18, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against renewal of the conditional marketing authorization for belantamab maf

Updated on:October 24,2023 77

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on: December 22,2023 13

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on:December 22,2023 13

Cancer and "Diet Myths": Beware of Pseudoscience in the Social Media Era

Updated on: July 06,2024 0

Cancer and "Diet Myths": Beware of Pseudoscience in the Social Media Era

Updated on:July 06,2024 0

Large study links sustained weight loss to reduced breast cancer risk

byAmerican Cancer SocietyCredit: CC0 Public DomainA large new study finds that women who lost weight after age 50 and kept it off had a lower risk of breast cancer than women whose weight remain

Updated on: December 22,2023 19

Large study links sustained weight loss to reduced breast cancer risk

byAmerican Cancer SocietyCredit: CC0 Public DomainA large new study finds that women who lost weight after age 50 and kept it off had a lower risk of breast cancer than women whose weight remain

Updated on:December 22,2023 19

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13, 2023Kristi RosaThe combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cel

Updated on: October 17,2023 178

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13, 2023Kristi RosaThe combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cel

Updated on:October 17,2023 178

Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia

September 5, 2023Kristi RosaThe National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma w

Updated on: October 12,2023 87

Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia

September 5, 2023Kristi RosaThe National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma w

Updated on:October 12,2023 87

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12, 2021Conor KillmurrayIn the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large

Updated on: October 24,2023 2

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12, 2021Conor KillmurrayIn the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large

Updated on:October 24,2023 2

The phenotypic plasticity effect of cancer cells and how to exploit it

by Michael Hesse,Max Planck SocietyMathematical model of tumor heterogeneity and phenotype switching: A detailed analysis. Credit: M.Raatz, MPI for Evolutionary BiologyCancer cells are notorious

Updated on: October 31,2023 20

The phenotypic plasticity effect of cancer cells and how to exploit it

by Michael Hesse,Max Planck SocietyMathematical model of tumor heterogeneity and phenotype switching: A detailed analysis. Credit: M.Raatz, MPI for Evolutionary BiologyCancer cells are notorious

Updated on:October 31,2023 20

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on: October 24,2023 32

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on:October 24,2023 32

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14, 2023Caroline SeymourHigher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutio

Updated on: October 24,2023 49

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14, 2023Caroline SeymourHigher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutio

Updated on:October 24,2023 49

Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis

byUniversity of Texas M. D. Anderson Cancer CenterCredit: Unsplash/CC0 Public DomainPatients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anem

Updated on: December 19,2023 10

Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis

byUniversity of Texas M. D. Anderson Cancer CenterCredit: Unsplash/CC0 Public DomainPatients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anem

Updated on:December 19,2023 10

Discovery of a protein controlling resistance to chemotherapy

byUniversité libre de BruxellesEMT is associated with intrinsic resistance to chemotherapy in SCCs. Credit:Nature(2023). DOI: 10.1038/s41586-023-05838-7Despite the recent development

Updated on: December 21,2023 10

Discovery of a protein controlling resistance to chemotherapy

byUniversité libre de BruxellesEMT is associated with intrinsic resistance to chemotherapy in SCCs. Credit:Nature(2023). DOI: 10.1038/s41586-023-05838-7Despite the recent development

Updated on:December 21,2023 10